Insufficient scRNA-seq data for expression of CYSLTR2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 97% | 299.11 | 2573 / 2642 | 85% | 2.55 | 602 / 705 |
adrenal gland | 100% | 1496.50 | 257 / 258 | 73% | 10.97 | 168 / 230 |
lung | 93% | 148.83 | 538 / 578 | 51% | 1.53 | 584 / 1155 |
thymus | 52% | 64.41 | 342 / 653 | 86% | 24.72 | 518 / 605 |
kidney | 56% | 65.66 | 50 / 89 | 70% | 22.10 | 634 / 901 |
skin | 61% | 81.03 | 1100 / 1809 | 48% | 6.79 | 226 / 472 |
heart | 100% | 950.16 | 861 / 861 | 0% | 0 | 0 / 0 |
spleen | 100% | 487.41 | 241 / 241 | 0% | 0 | 0 / 0 |
ovary | 88% | 300.67 | 158 / 180 | 10% | 0.19 | 42 / 430 |
intestine | 83% | 115.36 | 799 / 966 | 14% | 0.31 | 73 / 527 |
prostate | 79% | 110.09 | 193 / 245 | 15% | 0.26 | 74 / 502 |
breast | 40% | 39.00 | 185 / 459 | 41% | 0.82 | 458 / 1118 |
lymph node | 0% | 0 | 0 / 0 | 79% | 2.73 | 23 / 29 |
uterus | 52% | 76.21 | 88 / 170 | 18% | 0.58 | 82 / 459 |
peripheral blood | 69% | 114.20 | 642 / 929 | 0% | 0 | 0 / 0 |
adipose | 67% | 93.28 | 805 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 62% | 1.47 | 28 / 45 |
esophagus | 39% | 29.45 | 566 / 1445 | 20% | 0.37 | 36 / 183 |
pancreas | 2% | 0.87 | 5 / 328 | 53% | 1.05 | 95 / 178 |
blood vessel | 50% | 91.21 | 669 / 1335 | 0% | 0 | 0 / 0 |
stomach | 24% | 21.88 | 87 / 359 | 19% | 0.35 | 54 / 286 |
eye | 0% | 0 | 0 / 0 | 36% | 15.79 | 29 / 80 |
bladder | 10% | 13.43 | 2 / 21 | 19% | 0.84 | 95 / 504 |
liver | 12% | 8.35 | 26 / 226 | 15% | 0.31 | 62 / 406 |
muscle | 0% | 0.19 | 2 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006955 | Biological process | immune response |
GO_0061737 | Biological process | leukotriene signaling pathway |
GO_0007218 | Biological process | neuropeptide signaling pathway |
GO_0005575 | Cellular component | cellular_component |
GO_0005886 | Cellular component | plasma membrane |
GO_0004974 | Molecular function | leukotriene receptor activity |
GO_0008528 | Molecular function | G protein-coupled peptide receptor activity |
GO_0001631 | Molecular function | cysteinyl leukotriene receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CYSLTR2 |
Protein name | Cysteinyl leukotriene receptor 2 (G-protein coupled receptor protein) Cysteinyl leukotriene receptor 2 (CysLTR2) (G-protein coupled receptor GPCR21) (hGPCR21) (G-protein coupled receptor HG57) (HPN321) Cysteinyl leukotriene receptor 2 Cysteinyl leukotriene receptor 2 splice variant I (Cysteinyl leukotriene receptor 2 splice variant III) (Cysteinyl leukotriene receptor 2 splice variant IV) (Cysteinyl leukotriene receptor 2 splice variant V) (Cysteinyl leukotriene receptor 2 splice variant VII) |
Synonyms | CYSLT2R CYSLT2 KPG_011 PSEC0146 hCG_1647464 |
Description | FUNCTION: Receptor for cysteinyl leukotrienes. The response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium. The rank order of affinities for the leukotrienes is LTC4 = LTD4 >> LTE4. |
Accessions | ENST00000682523.1 ENST00000621321.1 A4ZKH2 Q5KU17 A0A1B0GXM0 Q9NS75 ENST00000282018.4 ENST00000622559.4 ENST00000614739.4 ENST00000617562.4 |